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Objective: To prospectively evaluate the safety and short-term therapeutic efficacy of switching monopolar radiofrequency 
ablation (RFA) with multiple electrodes to treat medium-sized (3.1-5.0 cm), hepatocellular carcinomas (HCC). 
Materials and Methods: In this prospective study, 30 patients with single medium-sized HCCs (mean, 3.5 cm; range, 3.1-
4.4 cm) were enrolled. The patients were treated under ultrasonographic guidance by percutaneous switching monopolar 
RFA with a multichannel RF generator and two or three internally cooled electrodes. Contrast-enhanced CT scans were 
obtained immediately after RFA, and the diameters and volume of the ablation zones were then measured. Follow-up CT 
scans were performed at the first month after ablation and every three months thereafter. Technical effectiveness, local 
progression and remote recurrence of HCCs were determined.
Results: There were no major immediate or periprocedural complications. However, there was one bile duct stricture during 
the follow-up period. Technical effectiveness was achieved in 29 of 30 patients (97%). The total ablation time of the 
procedures was 25.4 ± 8.9 minutes. The mean ablation volume was 73.8 ± 56.4 cm
3 and the minimum diameter was 4.1 ± 
7.3 cm. During the follow-up period (mean, 12.5 months), local tumor progression occurred in three of 29 patients (10%) 
with technical effectiveness, while new HCCs were detected in six of 29 patients (21%).
Conclusion: Switching monopolar RFA with multiple electrodes in order to achieve a sufficient ablation volume is safe and 
efficient. This method also showed relatively successful therapeutic effectiveness on short-term follow up for the treatment 
of medium-sized HCCs.
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INTRODUCTION
Radiofrequency ablation (RFA) is generally accepted as one 
of the most promising therapies for treating non-resectable 
hepatic tumors (1-3). RFA has recently been recognized 
as a potential alternative to surgery for small HCCs (3-8). 
However, compared with surgical treatment, a relatively high 
local tumor progression rate is regarded as a considerable 
shortcoming of RFA treatment (4, 8, 9). It has already 
been well-demonstrated in the literature that local tumor 
progression rates increase with larger-sized tumors (10, 11). 
The most significant factor contributing to high local 
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tumor progression rates when using conventional RFA 
systems with a single electrode is their inability to ablate a 
sufficient volume in the ablation zone to achieve complete 
tumor destruction (11-13). Until now, although several types 
of electrodes (14), including the internally cooled needle 
(15-17), perfused needle (18), and expandable needle (19, 
20), have been developed to achieve a greater ablation 
volume with a single application of RF energy, there are 
definite limitations to the ablation volume that can be 
destroyed using a single electrode. Therefore, consecutive 
overlapping ablations are required when using a single 
electrode RF system in order to create an ablation area 
sufficient to cover the tumor as well as the peripheral safety 
margins (13, 21-24). However, this is both time consuming 
and technically challenging as the gas bubbles formed 
disturb the repositioning of the electrode under ultrasound 
guidance, thereby leading to incomplete ablation (13, 25).
To increase the volume of coagulation with a single 
application, multiple electrode approaches have been 
designated using various modes including simultaneous 
monopolar (16, 26), switching monopolar (27-30), as well 
as bipolar and multipolar modes (31, 32). It has been 
proven that RFA using multiple electrodes creates a larger 
ablation volume than conventional single-electrode RFA 
(16, 26-34). Several preclinical in vivo experiments have 
shown that switching monopolar RFA can create a larger 
ablation volume than consecutive overlapping RFA (30, 
35, 36); however, there have been only two retrospective 
studies reporting the early clinical experience of switching 
monopolar RFA for malignant liver tumors (37, 38). In one 
retrospective study, as the therapeutic results of switching 
monopolar RFA for treating malignant liver tumors, 
including HCCs as well as metastases, were described 
without distinguishing each type of tumor, the clinical 
efficacy of switching monopolar RFA for HCC has not yet 
been determined. Furthermore, neither of these studies 
evaluated the therapeutic efficacy of switching monopolar 
RFA, depending on tumor size. Therefore, the purpose of 
this prospective study is to assess the safety and short-term 
therapeutic efficacy of switching monopolar RFA for treating 
medium-sized (3.1-5.0 cm in diameter) HCCs.
MATERIALS AND METHODS
Clinical Features of the Study Patients
Thirty patients with medium-sized HCCs (3.1-5.0 cm in 
diameter) were enrolled in this prospective study designed 
to evaluate the therapeutic efficacy of switching monopolar 
RFA at Seoul National University Hospital, from July 2007 
to January 2009. The inclusion criteria were as follows: 1) 
patients with a single HCC measuring 3.1-5 cm in diameter; 2) 
no evidence of vascular invasion or extrahepatic metastasis; 
3) no history of previous treatment for HCC; 3) liver function 
classified as Child-Pugh class A or B; 4) platelet count 
greater than 50,000/μL; 5) an international normalized ratio 
for prothrombin time greater than 1.7; and 6) follow up for 
six months or more. This prospective study was approved 
by our hospital’s Institutional Review Board, and written 
informed consent was obtained from each patient.
The clinical diagnosis of HCC in 29 study patients 
was made on the basis of the radiologic features of the 
tumors, which consist of a combination of typical arterial 
enhancement with washout on portal venous phase or 
equilibrium phase images on dynamic contrast-enhanced 
CT scans and/or dynamic MR images, and α-fetoprotein 
(AFP) values according to the clinical guidelines proposed 
by the American Association for the Study of Liver Diseases 
(39). In the remaining patients, the diagnosis of HCC 
was confirmed by percutaneous needle biopsy. Table 1 
summarizes the demographic, clinical, and laboratory 
findings of the study patients, while Table 2 summarizes the 
radiologic tumor findings.
Switching Monopolar Radiofrequency Ablation
All RFA procedures were performed percutaneously under 
ultrasonographic guidance using a multi-channel RFA 
system (Taewoong Medical, Goyang, Kyunggi, Korea) with 
multiple electrodes by one of three attending radiologists 
with at least five years of clinical experience in performing 
RFAs (range, 5-14 years). A combination of fentanyl citrate 
(Hana Pharm, Seoul, Korea), Midazolam (Hana Pharm, 
Seoul, Korea), and Ketamine (Huons, Hwaseong, Kyunggi, 
Korea) was administered intravenously in order to induce 
conscious sedation. Vital signs and cardiac status were 
monitored by pulse oxymetry and electrocardiography 
during the procedure.
The multi-channel generators produced a maximum power 
of 200 W at a frequency of 480-kHz, using the switching 
monopolar mode to heat tissue, and the application of 
power in an alternating fashion to two or three probes in 
order to avoid interference from multiple RF probes (Faraday 
cage Effect) (36). The switching system is based on the 
following protocol (36): the maximum power will switch 
electrodes after approximately 30 seconds if there is no Korean J Radiol 13(1), Jan/Feb 2012 kjronline.org 36
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impedance increase of at least 50 ohms above the baseline 
value. However, if there is an impedance value in one of 
the electrodes that exceeds 50 ohms above the baseline 
value, the current will automatically switch to the other 
electrode. In addition, if the impedance increases to 300 
ohms above the baseline value, no power will be applied to 
that particular electrode for 15 seconds.
We used two (n = 5) or three (n = 25) electrodes 
depending on the location and size of the target tumors; i.e., 
single, internally cooled electrodes (Well-point electrode
TM: 
Taewoong) were used in 19 patients, a combination of 
single and clustered electrodes were used in eight patients, 
and cluster electrodes were used in the remaining three 
patients. In general, three single electrodes (3 or 4 cm 
active tip) were preferentially used for HCCs measuring 3.1-
3.5 cm in diameter, along with a combination of single 
and cluster electrodes (2.5 cm active tip) or three cluster 
electrodes for HCCs larger than 3.5 cm in diameter. The 
electrodes had 17-gauge diameters and measured 15 cm in 
length. A chilled normal saline solution was infused into 
the lumens of the electrodes to maintain a tip temperature 
of 20-25°C. The electrodes were placed in the target tumors 
under ultrasonographic guidance, at an interprobe spacing 
of 1-2 cm, using an epigastric, subcostal or intercostal 
approach. Interelectrode spacing was generally kept to 
2 cm or less in order to prevent coagulation zones from 
becoming cleft or irregular (36, 37). When electrodes were 
placed in the target tumors, they were inserted through 
separate puncture sites and were initially activated for 18 
minutes (36). If subsequent ablations of the same tumor 
were required, they were performed for 8-18 minutes 
depending on both the tissue impedance and temperature. 
When ideal electrode placement was unsuccessful and failed 
to create an adequate ablation volume, the electrodes were 
repositioned. Repositioning of the applicators was required 
in 13 of the 30 study patients (43%).
To prevent track seeding after delivering RF energy, track 
ablation was performed while withdrawing the electrodes; 
the tip temperature of 90°C was attained by discontinuing 
cooling of the electrodes and maintained during retraction 
of the electrodes. In patients with peripheral tumors in 
the vicinity of the body wall, diaphragm or bowel artificial 
ascites were established using a 5% dextrose in water 
solution (D5W) in order to isolate the liver. Instillation of 
D5W was performed in 12 of the 30 study patients (33%). 
Table 1. Baseline Patient Characteristics 
Characteristics Value
Age (yr)






Platelet count (x 10
3/μL) 
Mean ± SD 115.6 ± 53.9
Range 31-241
Serum bilirubin (mg/dL)
Mean ± SD 1.1 ± 0.43
Range 0.5-2.3
Serum albumin (g/dL)
Mean ± SD 3.8 ± 0.42
Range 3.0-4.3
Serum AFP (ng/mL)
Mean ± SD 297.4 ± 1073.2
Range 1.1-5760.0
≤ 200 /> 200 26/4
Follow-up (months)
Mean ± SD 12.5 ± 4.7
Range 6-22
Note.— AFP = α-fetoprotein, HBV = hepatitis B virus, HCV = 
hepatitis C virus, LC = liver cirrhosis, SD = standard deviation
Table 2. Hepatocellular Carcinoma Characteristics
Maximal Tumor Diameter (cm)
Mean ± SD 3.6 ± 0.43
Range 3.1-4.4
Abutting vessels on CT scan: yes/no 4/26
Subcapsular tumor: yes/no 25/5
Tumor locations








Note.— Subcapsular tumor located less than 1 cm from 
liver margin and abutting vessels on CT scan, while tumor is 
contiguous to blood vessels (first to third branches of portal 
veins as well as first and second branches).Korean J Radiol 13(1), Jan/Feb 2012 kjronline.org 37
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Post-Treatment Assessment and Follow Up
Contrast-enhanced CT was performed immediately 
following the RFA procedure in order to assess both 
therapeutic responses and possible complications. 
Multiphasic liver CT scans composed of precontrast, arterial, 
and portal venous phase images, were routinely used. In 
total, 370 mgI/mL of iodinated contrast medium (iopromide, 
Ultravist 370; Schering, Berlin, Germany) at a dose of 1.5 
cc/kg body weight, was injected for 30 seconds using a 
power injector (Stellant Dual; Medrad, Indianola, PA), 
followed by 40 mL of normal saline chaser. The timing for 
the arterial phase scan was determined using a care bolus 
technique (Sensation 16; Siemens, Erlangen, Germany): 
the arterial phase scanning was automatically started 17 
seconds after the attenuation coefficient of the abdominal 
aortic blood reached 100 Hounsfield units. The portal 
venous phase scans were acquired 70 seconds after starting 
the contrast injection. 
Ablation was considered to be sufficient when the 
unenhanced ablation zone was larger than the treated 
tumor, while there was a tumor-free margin of at least 5 mm 
(40). If ablation was not sufficient on the CT immediately 
following the RFA procedure, additional ablations were 
performed. The assessment and treatment procedures were 
repeated until sufficient ablation was achieved during 
one hospital stay. In two of the 30 study patients (7%), 
an additional RFA was performed under ultrasonographic 
guidance. When sufficient ablation was confirmed, the 
ablation volume was carefully examined in the final images. 
Follow-up consisted of performing contrast-enhanced CT 
examinations at both the first and third months following 
ablation as well as subsequent contrast-enhanced CT 
examinations obtained every three months. 
To evaluate the efficacy of the switching RFA for inducing 
a large ablation volume, the maximum (Dmx) and minimum 
(Dmi) diameters were measured on a transverse section 
showing the largest ablation area by immediate follow-up 
CT. The vertical diameter (Dv), which is the length from the 
most cranial border to the most caudal border of the ablation 
zone, was also measured. The surrounding hyperemia area 
was not included in the ablation zone measurement. The 
volume of the ablation zone was evaluated by approximating 
the ablation zone to an ellipsoid using the following 
formula: π (Dv x Dmx x Dmi)/6 (36).
To evaluate the clinical efficacy of switching RFA 
for treating HCC, technical effectiveness, local tumor 
progression, new HCC recurrence, and tumor-free survival 
time were all determined (40, 41). Technical effectiveness 
was defined as when marginal nodular enhancements were 
not seen within the ablation zone on CT scans for at least 
one month following RFA (41) (Fig. 1). Intrahepatic tumor 
recurrence was categorized into two groups, which are local 
tumor progression and new HCC occurrence (41, 42). When a 
follow-up CT scan showed an enhanced area or enlargements 
at the margins of the treated tumors in which the technical 
effectiveness was documented on the one-month follow-up 
CT scan, it was determined to be local tumor progression 
(Fig. 2). New HCC occurrence was defined as development of 
a new HCC nodule away from the previously ablated lesion. 
Follow-up scans were interpreted by one of three attending 
physicians who were routinely involved in reading contrast-
enhanced abdominal CT scans as well as post-RFA CT scans 
in the Abdominal Division of Department of Radiology at 
our institution. Tumor-free survival time was defined as the 
time between RFA and local tumor progression, and the 
occurrence of new HCCs, extrahepatic metastasis or final CT 
Fig. 1. 71-year-old man with 4.3-cm-diameter hepatocellular carcinoma treated by switching monopolar radiofrequency ablation.
A. Contrast-enhanced T1-weighted image during arterial phase showing hyperenhancing hepatocellular carcinoma in segment VI (arrow). B. 
Immediate contrast-enhanced CT scan during portal venous phase after radiofrequency ablation procedure demonstrating creation of sufficient 
ablation zones to cover tumor (arrow). C. 14-month follow-up CT scan during portal phase showing no evidence of local tumor progression in 
region surrounding radiofrequency ablation zone (arrow).
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examination without overall tumor recurrence.
Complications were classified into major and minor 
categories according to the Society of Interventional 
Radiology (SIR) reporting standards for image-guided tumor 
ablation (41). When complications required treatment, 
an extended hospital stay resulting from irreversible and 
adverse sequelae were defined as major complications. 
All other complications were considered to be minor. 
Immediate complications were defined as those occurring 
within 24 hours of the procedure, while periprocedural 
complications were defined as those occurring within 30 
days of the procedure. We did not consider post-ablation 
pain as a complication. 
Statistical Analysis
Descriptive statistics for the following factors were 
obtained: demographic, clinical, laboratory and imaging 
findings in patients at the time of RFA; characteristics of 
the RFA procedures (number of needle insertions, total 
procedure time, ablation time, and delivered energy); 
ablation zones (diameter and volume); and complications. 
The Kaplan-Meier method was used to estimate the 
interval between RFA treatment and local tumor progression 
or tumor-free survival. A p value < 0.05 was considered to 
indicate statistical significance. All statistical analyses were 
performed using a statistical software program (SPSS for 
Windows, version 13.0; SPSS, Chicago, IL).
RESULTS
Characteristics of Radiofrequency Ablation Procedures 
The mean ablation time was 25.4 ± 8.9 minutes (range, 
15-48 minutes), while the mean time occupying an 
ultrasound suite for the RFA procedure, including conscious 
sedation, the RFA procedure, post-procedure evaluation, and 
recovery from the sedation, was 64 ± 19.8 minutes (range, 
35-120 minutes). The mean energy delivered was 165.5 
± 66.9 kJ (range, 67.9-323.5 kJ). Table 3 summarizes the 
Fig. 2. 63-year-old man with 4.3-cm-diameter hepatocellular carcinoma treated by switching monopolar radiofrequency ablation.
A. Pre-ablation CT scan during arterial phase showing hyperenhancing 4.3-cm-diameter hepatocellular carcinoma nodule (arrow). B. Immediate 
post-ablation CT scan during portal phase showing no definite residual enhancing tumor (arrow). C. Arterial phase nine-month follow-up CT scan 
showing local tumor progression (arrow) on superior side of radiofrequency ablation defect. D. Follow-up CT scan obtained immediately after 
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treatment characteristics. The mean volume of the ablations 
zones was 73.8 ± 56.4 cm
3 (range, 18.9-229.7 cm
3). The 
maximum, minimum and vertical diameters of the ablation 
zones on CT scans are summarized in Table 3.
Complications
There were no major, immediate or periprocedural 
complications. However, during the follow-up period one 
major complication occurred, which was RFA-related bile 
duct stricture accompanied by jaundice occurring six months 
following RFA (Fig. 3). Percutaneous biliary drainage was 
performed in this patient and eventually biliary stent placement 
was required. In addition, there were five minor complications: 
i.e. one immediate complication of mild hemoperitoneum and 
four minor biliary strictures involving peripheral intrahepatic 
bile ducts. None of the five minor complications was of clinical 
significance and therefore required no treatment.
Treatment Outcome and Follow Up
The mean follow-up duration was 12.5 ± 4.7 months 
(range, 6-22 months). No patient death and no extrahepatic 
recurrence occurred during the follow-up period. Technical 
effectiveness was achieved in 29 of 30 patients (97%). 
Local tumor progression occurred in three of 29 patients 
in whom technical effectiveness was achieved (10%). 
The mean local tumor-progression-free survival period 
was 18.1 ± 1.0 months. New HCCs were detected in five 
of 29 patients (17%). Both local tumor progression and 
a new HCC were seen in one patient. In this patient, 
occurrence of the new HCC nodule as well as the local tumor 
progression was detected on the 10-month follow-up CT 
scan, and the nodules were treated simultaneously with 
the RFA procedure. Overall tumor recurrence, local tumor 
progression, and/or new HCC occurrence, were detected in 
eight of 29 patients (28%). The mean tumor-free survival 
period was 17.5 ± 1.4 months. The cumulative tumor-free 
survival rates estimated at six months and one year post-
RFA were 97 ± 3.4% and 88 ± 6.8%, respectively. Table 
4 summarizes our study results with respect to technical 
failure, local tumor progression, and new HCCs. 
DISCUSSION
In our prospective study, switching monopolar RFA 
using multiple electrodes in patients with medium-sized 
HCCs, showed a high technical effectiveness rate (97%) 
and a good local tumor control rate (90%, 26 of 29). 
For achieving complete necrosis with RFA, treatment 
outcomes in our study using the multichannel RF generator 
and multiple electrodes, were significantly better than 
in previous studies in which percutaneous RFA used a 
conventional overlapping technique with a single electrode 
(11, 43). In a study using an internally cooled electrode by 
Livraghi et al. (11) and another study using an expandable 
electrode by Cabassa et al. (43), complete tumor necrosis 
was achieved in 61% and 53% of medium size HCCs (3.1-5.0 
cm in diameter), respectively. Furthermore, our local tumor 
recurrence rates achieved by switching monopolar RFA are 
comparable to those of a previous study with overlapping 
RFA with cluster electrodes (8-13%) using a percutaneous or 
surgical approach (44). The improved therapeutic efficiency 
of switching RFA can be attributed to its ability to produce 
a greater ablation volume compared with conventional RFA 
using a single electrode (37, 38).
In addition, our study demonstrated that switching 
Table 3. Characteristics of Radiofrequency Ablation 
Procedures and Ablation Zone
Characteristics Value





No. of inserted needles 
2° 5
3° 25
Ablation time (minutes)*  25.4 ± 8.9 (15-48)
Total duration of intervention
  (minutes)*
64 ± 19.8 (35-120)
Energy (kJ)* 165.5 ± 66.9 (67.9-323.5)
Ablation area*
Dmx (cm)* 5.4 ± 1.6 (3.8-9.7)
Dmi (cm)* 4.1 ± 7.3 (3.2-5.8)
Dv (cm)* 5.5 ± 1.6 (2.9-9.0)
Ablation volume (cm
3)*  73.8 ± 56.4 (18.9-229.7) 
Technical effectiveness rates 97% (29/30)
Note.— *Data are expressed as mean value ± standard 
deviation, with ranges in parentheses.
°Data are expressed as frequency. 
Total duration of intervention consists of time occupying 
ultrasound suite for entire radiofrequency ablation procedure; 
Dmx = maximum diameter on of largest transverse ablation 
area on portal phase dynamic CT scanning, Dmi = minimum 
diameter of largest transverse ablation area on portal phase 
dynamic CT scanning, Dv = length from cranial to caudal border 
of ablation zone.Korean J Radiol 13(1), Jan/Feb 2012 kjronline.org 40
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monopolar RFA was more time efficient compared with 
conventional RFA using a single electrode. In our study, 
it took 25.4 ± 8.9 minutes to sufficiently ablate tumors, 
which was a much shorter time than we had previously 
experienced using a conventional RFA system with a 
single electrode (four to six, 12-minute, single RF energy 
applications requiring 48-72 minutes). In our study, the 
mean ablation time using the switching RF system was also 
shorter than the times reported in previous studies using 
single-electrode RF systems (2, 45, 46). A previous study 
by Laeseke et al. (37) also demonstrated that the total 
ablation time of multiple-electrode RFA was reduced by 
approximately 54% compared with an equivalent number 
of ablations performed using a single-electrode system. 
Based on our study results, we believe that switching 
monopolar RFA provides a greater ability at achieving a 
satisfactory ablation zone for medium-size HCCs during a 
reasonable procedure time compared with the conventional 
and consecutive overlapping RF systems using single 
electrodes. Compared with the previous study (36) in which 
the switching controller system (Covidien, Boulder, CO) 
and 200 W generator was used, we used a multichannel RF 
generator having 3 RF amplifiers whose control is based 
on independent impedance changes. Although the basic 
mechanism of the multichannel RF generator for RF energy 
instillation is very similar to that of the switch controller of 
the Covidien RF system, it provides a potential advantage 
of controlling RF energy delivery to each electrode 
independently, based on impedance changes, and therefore, 
in a situation when one of the multiple electrodes has a 
markedly elevated impedance due to charring or placement 
of tip in a tissue with poor electrical conductivity, the 
multichannel RF generator may provide better heating 
efficiency than the switch controller system. 
In addition, we believe that the proposed multiple 
electrode RFA technique could be valuable for treating 
Fig. 3. 72-year-old man with 3.2-cm-diameter hepatocellular carcinoma treated by switching monopolar radiofrequency ablation.
A. Pre-ablation CT scan during arterial phase showing hyperenhancing 3.2-cm-diameter hepatocellular carcinoma nodule (arrow) in segment VI of 
liver. B. Six-month follow-up CT scan during portal phase showing mildly dilated intrahepatic ducts (arrowheads) with stricture at hilar level. No 
evidence of local tumor progression from radiofrequency ablation zone is evident (arrow).
A B
Table 4. Summary of Events: Technical Failures, Local Tumor Progression, and New Hepatocellular Carcinoma 
Occurrence 
Event Tumor Size (cm) Time Event Detected (mos) Post-Treatment Post-Treatment Results
Technical failures 3.3 1 TACE S
Local tumor progression 3.1 8 TACE S
3.3 10 RFA S
4.3 9 RFA S
New HCC occurrence 3.2 11 TACE S
3.3 10 RFA S
3.6 10 PEIT S
3.1 13 TACE S
3.1 6 TACE S
Note.— HCC = hepatocellular carcinoma, mos = months, PEIT = percutaneous ethanol injection therapy, RFA = radiofrequency 
ablation, S = successfully devascularized on follow-up contrast-enhanced CT, TACE = transcatheter arterial chemoembolization Korean J Radiol 13(1), Jan/Feb 2012 kjronline.org 41
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small tumors (2-3 cm in diameter) with a goal of obtaining 
similar local recurrence rates comparable to surgical 
resection (< 5% local recurrence rate), which can be 
possible only by creating enough safety margin (5-10 mm) 
around the tumor. Furthermore, it can be used for treating 
small malignant tumors (< 3 cm) located in the capsular 
or subcapsular portion, as a multiple electrode approach, 
can be used for creating large ablation zones without 
placing the electrode through the tumor (no tumor touch 
technique). However, there are also a few disadvantages of 
switching monopolar RFA with multiple electrodes including 
technical complexity and increased equipment cost related 
with the use of multiple electrodes. 
In our study, the ablation volume with the switching 
monopolar RFA (73.8 cm
3) was comparable to the results 
of several preclinical studies using switching monopolar 
RFA (30, 36, 42, 47). In our study, the maximum diameter 
of the ablation zone was 5.4 ± 1.6 cm with 2-3 (mean, 
2.89) electrodes spaced 1-2 cm apart. Several preclinical 
in vivo studies using switching monopolar RFA (30, 36, 42, 
47) reported an ablation zone with a maximum diameter 
of 4.2-5.1 cm using three single electrodes spaced 1.5-
2.0 cm apart; this was larger than the ablation volumes 
obtained with monopolar RFA using a single electrode. This 
improved efficiency of switching RFA may be attributed to 
the synergistic effect of proximal, concurrently inserted 
electrodes, as was proven by an in vivo study using porcine 
livers (30). The synergistic effect of switching the RF system 
was explained by thermal and electrical synergy, as well as 
the cooling effect of the vessels. First, multiple electrodes 
are placed in close proximity and heat is trapped among 
the electrodes, thus further raising the temperature of the 
treated tumors (thermal synergy). Furthermore, the switching 
system is not simultaneously powered, but alternately 
powered in order to avoid electrical shielding between 
multiple electrodes. In the switching system, the electrical 
current flowing from the powered electrodes to the region 
that is not powered following a voltage gradient, leads to 
higher temperatures within the spaces (33, 34). Lastly, 
vascular thrombosis of the ablation zone can reduce the 
cooling effect of the blood flow around adjacent electrodes. 
Recently, several studies evaluating the long-term outcome 
of consecutive overlapping RFA demonstrated various one-
year local recurrence rates from 4% to 17% (48-50). In 
our study, during a 12.5 ± 4.7-month follow-up period 
(range, 6-22 months), three of 29 patients with technical 
effectiveness showed local tumor progression within one 
year (10%). Indeed, it was very difficult to compare our 
study results with those of previous studies because the 
basic values included different mean tumor sizes, follow-
up duration, type of electrode used, and major etiology 
of the HCCs. However, considering the fact that our study 
included medium-sized HCCs (3.1-4.4 cm in diameter), 
our results of switching RFA with multiple electrodes are 
clinically acceptable and have better time efficiency than 
conventional overlapping RFAs using a single electrode. 
There may also be theoretical concerns over the safety 
of switching monopolar RFAs using multiple electrodes; 
these concerns include an increased risk of bleeding due to 
the placement of multiple electrodes, unexpected thermal 
damage to vital structures, and tumor seeding. However, 
our complication rates were similar to those of previous 
reports regarding complications using the conventional RF 
system with a single electrode (51-54). Only one major 
complication (3%, 1 of 30) and five minor complications 
(17%, 5 of 30) were noted in our study. Considering the 
usual types of complications, most are related to thermal 
damage to structures adjacent to the treated lesion, such as 
bile ducts. The risk of thermal damage may increase when 
a higher temperature is achieved with the more efficient 
ablation system used to achieve a larger ablation zone. 
Although all but one of our complications were clinically 
insignificant, further clinical studies in a larger population 
will be required in order to demonstrate the safety of 
switching monopolar RFAs using multiple electrodes.
Our study has limitations. First, as many tumors were 
located in subcapsular area (within 1 cm from the capsule), 
ablation size and volume created by switching monopolar 
RFA could have been underestimated. Second, the follow-
up period was too short to assess treatment outcomes 
regarding tumor progression and patient survival. Finally, 
as our study consisted of just one series of patients, it did 
not provide sufficient evidence to prove the superiority 
of switching monopolar RFA over that of consecutive 
overlapping RFA. Therefore, a randomized, controlled trial 
will be needed to prove this. Despite these limitations, our 
study was adequate as a preliminary report to evaluate the 
short-term efficacy of using switching monopolar RFA to 
treat medium-sized HCCs.
In conclusion, switching monopolar RFA is safe, time-
efficient, can achieve an adequate ablation volume, and 
shows short-term therapeutic effectiveness for treating 
medium-sized HCCs.Korean J Radiol 13(1), Jan/Feb 2012 kjronline.org 42
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